Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian markets trade negatively
Wed, 12 Aug 11:30 am

After opening the day on a bearish note, the Indian Indices have continued to trade negatively. Sectoral indices are trading on a mixed note with energy and metal stocks leading the losers. However, software and pharma stocks are trading in the green.

The BSE-Sensex is trading lower 90 points (down 0.33%) and the NSE-Nifty is trading down 38 points (down 0.45%). The BSE Mid Cap index and the BSE Small Cap index are also trading negatively, down by 1% and 0.6% respectively. The rupee is trading at 64.81 to the US dollar.

Stocks in the FMCG sector are trading on a discouraging note with Jyothy Labs and Marico Ltd bearing the maximum burnt. As per an article in Business Standard, price cuts by FMCG companies have failed to boost their Q1 volume growth. This was after they witnessed that a fall in realizations due to price cuts was not compensated by an equivalent rise in volume growth. Of the top 10 FMCG companies by market capitalizations, six saw lower revenue growth as compared to the corresponding year ago quarter. However, falling input costs due to softening of raw materials and crude oil prices have aided strong margin expansion for these companies. Notably, of the above ten, nine saw strong EBIDTA margin expansion.

Indian pharma stocks are trading mixed with Sun Pharma leading the gainers and Dishman Pharma leading the losses. According to financial times, India's largest pharma company by revenue Sun Pharmaceuticals reported a 60% YoY decline in its net profits for the quarter ended June 2015. This was mainly due to the one time and exceptional charges of Rs 6.8 bn which relates to impairment of fixed assets, goodwill and other related costs. All of these were following the acquisition of Ranbaxy. Revenues for the company witnessed a rise of 3% on a YoY basis. Presently the scrip of Sun Pharmaceuticals is trading up by 4.2%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets trade negatively". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.